{"entity":{"id":"eisbach-bio","kind":"company","name":"Eisbach Bio","aka":[],"tldr":"Eisbach Bio develops small-molecule cancer medicines. Its lead tablet, EIS-12656, blocks a DNA repair enzyme called ALC1 and is in an early trial in advanced solid tumours with defects in DNA repair.","summary":"Eisbach Bio GmbH is a privately held clinical-stage company in Martinsried, Planegg, near Munich. It uses an AI-guided platform called ALLOS to design small molecules that target the activated state of enzymes. EIS-12656 is an oral, brain-penetrant, allosteric inhibitor of the chromatin helicase ALC1 (CHD1L), studied in homologous recombination deficient tumours; the phase 1/2 MATCH trial (NCT06525298) at MD Anderson tests it alone and with olaparib or trastuzumab deruxtecan, the first patient was dosed in September 2024, and the trial is co-funded by the Cancer Focus Fund. Other programmes target CHD1 in PTEN-deficient tumours and WRN in MSI-high cancers. The company reported completing a phase 1 trial of the helicase inhibitor EIS-10700 in May 2024 and a CPRIT grant in November 2024. Its first registered cancer trial, NCT06525298, was posted on ClinicalTrials.gov in July 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.eisbach.bio/"},{"label":"Eisbach: first patient dosed with EIS-12656 (September 2024)","url":"https://www.eisbach.bio/post/eisbach-announces-first-patient-dosed-in-phase-1-2-trial-for-eis-12656-a-first-in-class-allosteric"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06525298"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","No financing amounts or named equity investors on the pages read; the CPRIT grant amount was not read.","ALC1 (CHD1L) has no OnCo target record and is named in text only.","Company website read on 29 October 2026."],"hq":"Planegg","country":"DE","companyType":"biotech","website":"https://www.eisbach.bio/","investors":[],"funding":[]},"route":"/companies/eisbach-bio/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"}],"trial":[{"id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/"}]}}